Semaglutide
GLP-1 Receptor Agonist | GPCR Bias & Incretin Research
Trusted by 85+ research professionals, labs, and institutions nationwide
Third-party Tested
COA Verified
Cold Storage
Same-day DeliveryFor research use only. Analytical reference material for in vitro work by qualified researchers. Learn more
Active Batch
SEM-202602-J1
Purity
99.302%
Third-party TestedCOA VerifiedCold StorageSame-day DeliverySemaglutide is a synthetic GLP-1 (glucagon-like peptide-1) receptor agonist with a molecular weight of 4114 g/mol, molecular formula C187H291N45O59, and CAS number 910463-68-2. Engineered with an aminoisobutyric acid substitution at position 8 and a C18 fatty diacid linker, Semaglutide has been extensively characterized in published research for its GLP-1 receptor binding affinity, resistance to DPP-4 enzymatic degradation, and albumin-binding pharmacokinetic properties. Published preclinical and clinical studies have investigated Semaglutide's downstream effects on cAMP-mediated insulin secretion pathways, hypothalamic appetite signaling, cardiovascular biomarker modulation, and hepatic lipid metabolism in various research models. This compound is supplied as a research reagent for incretin receptor and metabolic pathway investigation. It is not intended for unauthorized human or veterinary use, and no claims regarding therapeutic efficacy are made or implied.
Semaglutide is a synthetic GLP-1 (glucagon-like peptide-1) receptor agonist with a molecular weight of 4114 g/mol, molecular formula C187H291N45O59, and CAS number 910463-68-2. Engineered with an aminoisobutyric acid substitution at position 8 and a C18 fatty diacid linker, Semaglutide has been extensively characterized in published research for its GLP-1 receptor binding affinity, resistance to DPP-4 enzymatic degradation, and albumin-binding pharmacokinetic properties. Published preclinical and clinical studies have investigated Semaglutide's downstream effects on cAMP-mediated insulin secretion pathways, hypothalamic appetite signaling, cardiovascular biomarker modulation, and hepatic lipid metabolism in various research models. This compound is supplied as a research reagent for incretin receptor and metabolic pathway investigation. It is not intended for unauthorized human or veterinary use, and no claims regarding therapeutic efficacy are made or implied.
For Research Purposes Only
By purchasing this product, you acknowledge that you are a qualified researcher. Not for human or animal consumption.
Learn More
2D Structure
Known Synonyms
Identifiers
Molecular Formula
C187H291N45O59
InChIKey
DLSWIYLPEUIQAV-CCUURXOWSA-N
InChI
Computed Properties
2D Structure
Known Synonyms
Identifiers
Computed Properties
Semaglutide — Research Reference
A long-acting GLP-1 receptor agonist — a benchmark reference compound in incretin pharmacology and GPCR-bias research.
What is Semaglutide?
Semaglutide is a 31-amino-acid synthetic peptide engineered as a GLP-1 receptor agonist, modified from native human GLP-1 with two amino-acid substitutions (Aib at position 8, Arg at position 34) and a C18 fatty-diacid side chain that stabilises the molecule through serum albumin binding. Since 2017 it has become a standard reference compound in incretin pharmacology research, with peer-reviewed publications spanning GLP-1R signalling bias, β-cell electrophysiology, DPP-4 resistance characterisation, and body-composition rodent models.
Mechanism in research literature
GLP-1 receptors are class B GPCRs expressed on pancreatic β-cells and several peripheral tissues. The published mechanistic literature on semaglutide describes glucose-dependent potentiation of insulin secretion in cultured β-cells, biased signalling profiles at GLP-1R (Gαs-cAMP versus β-arrestin recruitment), and extended receptor occupancy enabled by albumin-binding. The Aib substitution at position 8 confers resistance to DPP-4 cleavage — the enzymatic step that limits native GLP-1 to a ~2-minute half-life. Together these modifications make semaglutide a useful tool compound for studying sustained GLP-1R engagement in cell-culture systems. Reviews of the mechanistic literature are available in Endocrine Reviews and Molecular Metabolism; relevant citations are linked in the Studies tab.
Documented research applications
Documented research contexts for semaglutide include pancreatic β-cell electrophysiology, GLP-1R signalling-bias assays, DPP-4 resistance characterisation, adipocyte and hepatocyte metabolism in cell-culture systems, and pharmacokinetic profiling across formulations. It is among the most active reference compounds in current incretin pharmacology research. Researchers interested in multi-receptor incretin pharmacology often study semaglutide alongside tirzepatide (dual GIP/GLP-1) and retatrutide (triple GIP/GLP-1/glucagon) — Noxa Labs supplies all three as analytical reference materials.
Reconstitution
Reconstitute lyophilised semaglutide with bacteriostatic water. A common working concentration is 2 mg/mL: add 2 mL BAC water to a 4 mg vial. Direct the diluent against the vial wall and swirl gently to dissolve.
Storage & stability
Lyophilised semaglutide is stable at 2–8 °C for extended periods. Reconstituted semaglutide should be stored refrigerated at 2–8 °C and used within 4 weeks per the typical stability window noted on COAs.
Availability in the Philippines
Semaglutide ships nationwide from Noxa Labs Metro Manila cold storage in 2–3 business days. Same-day dispatch on weekday orders before 2 PM PHT.
Frequently asked questions
All Noxa Labs products are supplied strictly as analytical reference materials for qualified in vitro research. They are not pharmaceutical products, food supplements, or substances for human or animal consumption.
Pair Semaglutide with these peptides
Verified compounds researchers commonly add to their workflow.
BAC Water
3 ml
Retatrutide
10 mg
Tirzepatide
10 mg
BPC-157
10 mg
CJC-1295 (No DAC) + Ipamorelin (Blend)
10 mg
GHK-Cu
100 mg
BAC Water
3 ml
Retatrutide
10 mg
Tirzepatide
10 mg
BPC-157
10 mg
